Lenalidomide hemihydrate

  Cat. No.:  DC67327   Featured
Chemical Structure
847871-99-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of thalidomide, functions as a molecular glue and is an orally active immunomodulator. It acts as a ligand for the ubiquitin E3 ligase cereblon (CRBN), facilitating the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase complex. Lenalidomide hemihydrate specifically inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes the release of IL-2 from T cells.
Cas No.: 847871-99-2
Chemical Name: Lenalidomide hemihydrate
Synonyms: Lenalidomide (hemihydrate);3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione,hydrate;CC-5013 hemihydrate;CC5013 hemihydrate;Lenalidomide hemihydrate;TS-08295;191732-72-6, anhydride;Q27293963;DA-74946;Lenalidomide hydrate (JAN);(+/-)-2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, hydrate (2:1);(3RS)-3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione hemihydrate;Revlimid (TN);3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;hydrate;Lenalidomide hydrate [JAN];AKOS030526922;XIB87199;Lenalidomide hydrate;SCHEMBL33695;D09813;PD038108;847871-99-2;LENALIDOMIDE HEMIHYDRATE [WHO-DD];3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione hemihydrate;(RS)-3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione hemihydrate;2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, hydrate (2:1);UNII-XQT0NAW8WD;XQT0NAW8WD;bis(3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione) hydrate
SMILES: O=C1CCC(N2CC3C(=CC=CC=3N)C2=O)C(=O)N1.O.O=C1CCC(N2CC3C(=CC=CC=3N)C2=O)C(=O)N1
Formula: C26H28N6O7
M.Wt: 536.536525726318
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
Cat. No. Product name Field of application
DC67413 MRT-23227
DC67412 MRT-3486
DC67411 MRT-7612
DC67410 MRT-10350
DC67407 IKZF1-degrader-1 IKZF1-degrader-1 (Compound 9-B) is a highly potent molecular glue that achieves sub-nanomolar degradation of IKZF1 (DC50 = 0.134 nM), demonstrating significant therapeutic potential for targeting IKZF1-dependent malignancies.
DC67406 EM12-FS EM12-FS is a bifunctional CRBN modulator that engages cereblon at His353 while functioning as a molecular glue to induce NTAQ1 degradation. Demonstrating favorable pharmacokinetics, it exhibits a human plasma half-life of 196 minutes, supporting its therapeutic potential.
DC67405 Acetyl-cyclosporin A aldehyde Acetyl-cyclosporin A aldehyde is a chemically modified derivative of cyclosporin A (HY-B0579), featuring an acetyl group and a reactive aldehyde moiety. The parent compound, cyclosporin A, is a dual-function molecule that both inhibits calmodulin signaling and binds cyclophilin, thereby blocking NF-AT nuclear translocation and inducing mitochondrial dysfunction.
DC67404 QS-57 QS-57 is a bifunctional degrader that combines BRD4-targeting PROTAC activity with 14-3-3 molecular glue properties.
DC67403 KRAS ligand 4 KRAS ligand 4 (compound 2) is a SOS1-targeting bifunctional molecular glue that suppresses oncogenic signaling by degrading key KRAS pathway components, evidenced by reduced pERK and pS6 levels. It demonstrates broad-spectrum activity against diverse KRAS mutations, disrupting proliferation across resistant cancer models.
DC67402 Pomalidomide-15N,13C5 Pomalidomide-15N,13C5 is a stable isotope-labeled variant of pomalidomide (HY-10984), a third-generation immunomodulatory drug that functions as a cereblon-directed molecular glue. This compound mediates targeted ubiquitination and degradation of Ikaros family transcription factors (IKZF1/3) through recruitment of the CRL4CRBN E3 ligase complex, underpinning its therapeutic mechanism.
X